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Weekends-oﬀ  efavirenz-based antiretroviral therapy in 
HIV-infected children, adolescents, and young adults 
(BREATHER): a randomised, open-label, non-inferiority, 
phase 2/3 trial
The BREATHER (PENTA 16) Trial Group*
Summary
Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with 
long-acting drugs oﬀ ers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare 
short cycle therapy (5 days on, 2 days oﬀ  ART) versus continuous therapy (continuous ART).
Methods In this open-label, non-inferiority trial (BREATHER), eligible participants were aged 8–24 years, were stable on 
ﬁ rst-line efavirenz with two nucleoside reverse transcriptase inhibitors, and had HIV-1 RNA viral load less than 
50 copies per mL for 12 months or longer. Patients were randomly assigned (1:1) to remain on continuous therapy or 
change to short cycle therapy according to a computer-generated randomisation list, with permuted blocks of varying 
size, stratiﬁ ed by age and African versus non-African sites; the list was prepared by the trial statistician and randomisation 
was done via a web service accessed by site clinician or one of the three coordinating trials units.The primary outcome 
was the proportion of participants with conﬁ rmed viral load 50 copies per mL or higher at any time up to the 48 week 
assessment, estimated with the Kaplan-Meier method. The trial was powered to exclude a non-inferiority margin of 12%. 
Analyses were intention to treat. The trial was registered with EudraCT, number 2009-012947-40, ISRCTN, number 
97755073, and CTA, number 27505/0005/001-0001.
Findings Between April 1, 2011, and June 28, 2013, 199 participants from 11 countries worldwide were randomly assigned, 
99 to the short cycle therapy and 100 to continuous therapy, and were followed up until the last patient reached 48 weeks. 
105 (53%) were men, median age was 14 years (IQR 12–18), and median CD4 cell count was 735 cells per μL (IQR 576–968). 
Six (6%) patients assigned to the short cycle therapy versus seven (7%) assigned to continuous therapy had conﬁ rmed 
viral load 50 copies per mL or higher (diﬀ erence –1·2%, 90% CI –7·3 to 4·9, non-inferiority shown). 13 grade 3 or 4 
events occurred in the short cycle therapy group and 14 in the continuous therapy group (p=0·89). Two ART-related 
adverse events (one gynaecomastia and one spontaneous abortion) occurred in the short cycle therapy group compared 
with 14 (p=0·02) in the continuous therapy group (ﬁ ve lipodystrophy, two gynaecomastia, one suicidal ideation, one 
dizziness, one headache and syncope, one spontaneous abortion, one neutropenia, and two raised transaminases).
Interpretation Non-inferiority of maintaining virological suppression in children, adolescents, and young adults was shown 
for short cycle therapy versus continous therapy at 48 weeks, with similar resistance and a better safety proﬁ le. This short 
cycle therapy strategy is a viable option for adherent HIV-infected young people who are stable on efavirenz-based ART.
Funding UK National Institute for Health Research Health Technology Assessment; UK Medical Research Council; 
European Commission; PENTA Foundation; INSERM SC10-US19, France.
Copyright © The BREATHER (PENTA 16) Trial Group. Open Access article distributed under the terms of CC BY.
Introduction
Antiretroviral therapy (ART) has substantially improved 
the prognosis for HIV-infected children, transforming 
HIV-1 infection from a life-threatening disease to a chronic 
infection. Furthermore, with new evidence,1 universal ART 
is now recommended2,3 for all people living with HIV, 
including children and adolescents, even without major 
immunosuppression or HIV-related symptoms. Therefore, 
the population of children, adolescents, and young adults 
on life-long ART is growing.4 For this population, innovative 
treatment strategies are needed to address their lifestyle 
needs, to help maintain long-term retention-in-care, and to 
improve adherence to ART, which is particularly 
problematic during adolescence.4–6
Short cycle therapy aims to maintain suppression of 
HIV-1 RNA during planned short breaks from ART, 
thereby reducing ART intake, long-term toxic eﬀ ects, and 
costs. First proof-of-concept studies suggested the 
feasibility of a 7 days on and 7 days oﬀ  ART strategy;7–9 
however, this approach proved inferior to continuous 
therapy in two randomised controlled trials in adults.10,11 
Single-arm studies with shorter breaks in ART (4 days on 
and 3 days oﬀ ) reported inconsistent results.12,13 However, 
two small randomised controlled trials conﬁ rmed that a 
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short cycle therapy strategy of 5 days on and 2 days oﬀ  ART 
is achievable: in the FOTO trial, including 60 US adults,14,15 
and in a larger randomised controlled trial in 103 Ugandan 
adults,10 short cycle therapy was non-inferior to continuous 
therapy in terms of maintained viral load suppression over 
48 weeks with the added beneﬁ t of less toxicity. Most 
participants in both trials were on efavirenz, which has a 
long plasma half-life (40–91 h), and lamivudine, which has 
an intermediate long intracellular half-life (22 h).16 
However, whereas participants in the US study received 
tenofovir disoproxil fumarate as the third drug (intracellular 
half-life 60–180 h),16 those in the Ugandan trial received 
shorter-acting stavudine or zidovudine.
No randomised trials of short cycle therapy have been 
done in children or adolescents, who face longer-term ART 
than adults. We aimed to assess whether short cycle therapy 
on ﬁ rst-line efavirenz-based ART in children, adolescents, 
and young adults was non-inferior to continous therapy 
in terms of maintaining virological suppression and 
adherence to ART, while improving quality of life.
Methods
Study design and participants
In this open-label, randomised, parallel group non-
inferiority phase 2/3 trial (BREATHER [BREaks in 
Adolescent and child THerapy using Efavirenz and two 
nRtis] PENTA 16), participants aged 8–24 years were eligible 
if they had a CD4 cell count 350 cells per μL or higher, 
suppressed viral load less than 50 copies per mL for at least 
12 months on an efavirenz based regimen with two or three 
nucleoside or nucleotide reverse transcriptase inhibitors 
(NRTIs) and no previous treatment failure (ﬁ rst-line ART). 
Children on nevirapine or boosted protease inhibitor ART 
who had not had treatment failure and with undetectable 
viral load could be enrolled if they substituted efavirenz and 
viral load remained undetectable for 12 weeks or longer 
before enrolment. Previous two-drug ART, substitution of 
NRTIs, or both were allowed, provided these were not for 
regimen failure. Previous monotherapy was only allowed if 
taken perinatally for prevention of mother-to-child-
transmission. Participants were not eligible if they were 
pregnant, on concomitant medications for acute illness, or 
if their creatinine or liver transaminases results were 
grade 3 or higher at screening. Parents or guardians and 
older participants provided written consent; young children 
gave assent appropriate for age and knowledge of HIV 
status, as per guidelines for each participating country.
The trial protocol was approved by the ethics 
committees in participating centres in Europe, Africa, 
and the Americas, and is available online.
For the protocol see http://
penta-id.org/attachment/up/
a2015/BREATHER_PENTA16_
protocol_version_1_9.pdf
Research in context
Evidence before this study
We searched PubMed up to March 1, 2016, with the search terms 
“HIV” AND (“short” AND “cycle” OR “short-cycle”) AND “therapy” 
and the references from the retrieved manuscripts. More than a 
decade ago, small proof-of-concept studies in adults suggested 
that structured treatment interruptions with 7 days on and 
7 days oﬀ  cycles of antiretroviral therapy (ART) could maintain 
virological suppression, particularly if drugs with long half-lives 
were used. However, this strategy proved inferior to continuous 
therapy in two randomised controlled trials in adults. Single-arm 
studies of a short-cycle therapy strategy with 4 days on and 
3 days oﬀ  showed inconsistent results: although there was no 
conﬁ rmed viral rebound in adults on diﬀ erent ART regimens in a 
French study, a study in highly treated adolescents and young 
adults on protease inhibitor-based therapy in the USA showed 
high rates of viral rebound. Adult studies of short cycle therapy 
with 2 days per week oﬀ  efavirenz-based ART showed promising 
results: following a single arm study of 5 days on and 2 days oﬀ  
ART, which showed rates of virological suppression of about 90% 
over 48 weeks, two small randomised controlled trials in adults 
(one US, one Ugandan) conﬁ rmed non-inferiority of maintaining 
virological suppression with this short cycle therapy strategy 
compared with continuous therapy. No published trials have 
assessed 5 days on and 2 days oﬀ  ART in children or adolescents.
Added value of this study
To our knowledge, this is the ﬁ rst randomised controlled trial to 
investigate the feasibility and acceptability of efavirenz-based 
short cycle therapy (5 days on and 2 days oﬀ ) in a geographically 
diverse group of children, adolescents, and young adults with no 
previous treatment failure. The short cycle therapy was 
acceptable and non-inferior in terms of maintaining virological 
suppression (including to very low viral loads). No signiﬁ cant 
diﬀ erences were noted in immune activation, total HIV-1 DNA, 
or development of resistance, and the short cycle therapy group 
had fewer ART-related adverse events than did the continuous 
therapy group. Additionally, participants expressed a strong 
preference for this short cycle therapy compared with continuous 
treatment, once they had adapted to the new routine.
Implications of all the available evidence
The ﬁ ndings of this trial, supported by previous adult studies, 
show that a short cycle therapy strategy with 5 days on and 
2 days oﬀ  efavirenz -based ART with a standard dose of 
efavirenz (maximum 600 mg adult equivalent daily dose) is a 
viable option for virologically suppressed children, adolescents, 
and young adults with 29% reduction in the cost of drugs. 
2 year extended follow-up of the trial is ongoing to address 
sustainability of this strategy over a longer duration and results 
will be available in 2017. Further studies are warranted to assess 
short cycle therapy with lower doses of efavirenz and other 
long-acting ART regimens in settings with less frequent viral 
load testing than the quarterly monitoring done in trials 
reporting to date. 
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Randomisation and masking
Patients were randomly assigned (1:1) to remain on 
continuous therapy or change to short cycle therapy and 
randomisation was done centrally by the MRC Clinical 
Trials Unit at UCL (London, UK), according to a 
computer-generated randomisation list, using permuted 
blocks of varying size, stratiﬁ ed by age (8–12 years, 
13–17 years, 18–24 years) and site (African vs non-
African). The randomisation list was prepared by the trial 
statistician and securely incorporated within the 
database. Randomisation of study participants was done 
via a web service accessed by site clinician or one of the 
three coordinating trials units.
Procedures
An initial 3 week randomised pilot safety phase in 
selected clinical centres was done in 32 participants (in 
which 15 participants were allocated to the short cycle 
therapy group) to ensure those in the short cycle therapy 
group maintained undetectable viral load (<50 copies 
per mL) after the 2 day break (Saturday and Sunday) and 
before resuming weekday ART on Monday. Recruitment 
to the main trial commenced after review of three 
consecutive Monday morning viral load results per 
participant by the Independent Data Monitoring 
Committee (IDMC).
In the main trial, participants randomly assigned to 
short cycle therapy chose 2 consecutive days oﬀ  ART 
(Friday and Saturday or Saturday and Sunday; 
occasionally 2 other days: referred to as weekends oﬀ ), 
and continued this cycle throughout. Participants on 
continuous therapy remained on continuous efavirenz-
based ART. Substitutions for simpliﬁ cation (except 
efavirenz) or toxicity (all drugs) were allowed. Participants 
were randomised 2–4 weeks after screening and assessed 
clinically at weeks 4 and 12, then every 12 weeks until the 
last participant had completed 48 weeks’ follow-up. 
Examination for lipodystrophy, Tanner stage, and a 
pregnancy test (in postmenarchal girls) were done at 
randomisation and repeated every 24 weeks.
Viral load and T lymphocytes were measured at every 
visit; participants with viral load of 50 copies per mL or 
higher had a repeat test within 1 week; those on short cycle 
therapy with conﬁ rmed viral rebound (two test results 
with viral load >50 copies per mL) recommenced 
continuous ART. Additional assessment of treatment 
adherence and a stored sample for resistance testing were 
requested for all participants with viral rebound. 
Haematology and biochemistry tests were done at 
screening and randomisation; thereafter, haematology 
was done every 12 weeks and biochemistry as per local 
practice. Blood lipids, including total cholesterol, high 
density lipoprotein, low density lipoprotein, and very low 
density lipoprotein, were measured at weeks 0, 24, and 48. 
Plasma and cells were stored for additional immunology 
and virology tests (see below) at baseline and weeks 4, 8, 
and 12, and then every 12 weeks for plasma and 24 weeks 
for cells. Questions on compliance to the strategy were 
asked at every follow-up visit. Adherence questionnaires 
were completed by carers and participants at weeks 0, 4, 
12, 24, and 48. Acceptability questionnaires for those 
randomised to short cycle therapy were completed at 
randomisation and at ﬁ nal visit (or at time of change from 
short cycle therapy to continous therapy if earlier).
The trial incorporated three substudies. The virology 
and immunology substudy assessed low level viraemia 
(viral load <20 copies per mL), total HIV-1 DNA, and 
19 biomarkers of inﬂ ammation, vascular injury, 
and disordered thrombogenesis; all were measured 
retrospectively on stored plasma and cell samples. The 
ultrasensitive quantitative HIV-1 RNA and DNA assays 
used the Qiagen QIAsymphony SP (Hilden, Germany) 
for nucleic acid extraction. An ABI Prism 7500 real-time 
thermal cycler (Foster City, CA, USA) was used for 
ampliﬁ cation of HIV-1 RNA and DNA using Invitrogen 
RT-PCR (Waltham, MA, USA) and Qiagen Multiplex 
PCR (Hilden, Germany) reagents, respectively. An in-
house standard curve calibrated against the WHO HIV 
International standard in IU per mL was used for HIV-1 
RNA quantiﬁ cation (appendix). The quantitation of HIV-
1 DNA was based on a standard curve using the 8E5 cell 
line, which carries one HIV proviral genome per cell; cell 
numbers were estimated with the single copy gene for 
pyruvate dehydrogenase; results were reported as copies 
of HIV-1 DNA per million cells.
19 biomarkers (thrombomodulin, ICAM-1, ICAM-3, 
VCAM-1, CD62E, CD62P, VEGF, angiopoietin 1 and 2, 
serum amyloid, C-reactive protein, interleukin 1Ra, 
interleukin 6, interleukin 8, interleukin 10, TNFα, MCP-1, 
tissue factor, and D-dimers) were analysed with Meso 
Scale Discovery (Gaithersburg, MD, USA) or by ELISA 
kits (Quantikine ELISA Human Coagulation Factor III/
Tissue Factor [R&D Systems, MN, USA] and 
TECHNOZYM D-dimer ELISA assay Technoclone 
[Vienna, Austria]). CD4 and CD8 lymphocyte subsets were 
quantiﬁ ed locally on fresh samples; CD45RA and CD45RO 
subpopulations of CD4 and CD8 cells were assessed on 
fresh or stored frozen cell samples at selected sites.
The adherence substudy assessed adherence in 
participants from selected sites by recording bottle 
openings using a Medication Event Monitoring System 
(MEMS) capped container. MEMS caps were placed on 
the container with most frequently taken antiretrovirals.
The longitudinal qualitative substudy focused on 
participants’ experiences of the trial and acceptability of 
short cycle therapy.17
Outcomes
The primary endpoint was conﬁ rmed viral load of 
50 copies per mL or higher by week 48. Secondary 
outcomes were: conﬁ rmed viral load of 400 copies per mL 
or higher by week 48; cumulative number and type of 
major HIV-1 RNA resistance mutations in those with 
viral rebound; change in CD4% and CD4 cell count, 
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glucose, blood lipids from baseline to week 48; changes 
in ART regimen; change back to continuous therapy 
(short cycle therapy only); adherence; acceptability (short 
cycle therapy); division of AIDS grade 3 or 4 clinical or 
laboratory adverse events,18 and treatment-modifying 
adverse events of any grade; and new US Centers for 
Disease Control (CDC) stage B or C diagnoses or death.
Statistical analysis
160 participants (80 per group) provided 80% power to 
exclude a non-inferiority margin of 12% for the diﬀ erence 
in proportion of participants reaching the primary 
endpoint, assuming 10% of participants have conﬁ rmed 
viral load 50 copies per mL or higher in the continuous 
therapy group and a one-sided α of 0·05 (two-sided 
α=0·1). The Trial Steering Committee decided to 
continue recruitment until the end of the planned 
randomisation period to allow sites to recruit patients 
already invited for screening and to avoid the study being 
underpowered if the proportion of participants reaching 
the primary endpoint in the continuous therapy group 
was lower than expected (the Trial Steering Committee 
did not have access to event rates during the trial).
In the primary, intent-to-treat analysis, the proportion 
of participants who had viral rebound (≥50 copies per mL) 
was estimated with Kaplan-Meier methods, with 
adjustment for baseline stratiﬁ cation factors, censoring 
at week 54 (upper band of week 48 assessment window) 
or last follow-up date if not seen at week 48. The 
diﬀ erence in proportion (between the short cycle therapy 
group and continuous therapy group) of participants 
who had viral rebound was estimated and two-sided 90% 
CIs of the diﬀ erence was obtained with bootstrap SE 
(1000 replicates).19 In a prespeciﬁ ed sensitivity analysis 
on the per-protocol population, individuals were 
censored if they had a break in treatment for longer than 
7 days, discontinued efavirenz for longer than 7 days, or 
changed strategy to continuous therapy for reasons 
other than viral rebound. The intent-to-treat analysis was 
also repeated without adjustment for stratiﬁ cation 
factors. Conﬁ rmed viral load of 400 copies per mL or 
higher was estimated by the same approach. Major 
resistance mutations were summarised.
Immunology (including substudy biomarkers), HIV-
DNA, haematology, biochemistry, and lipids were 
assessed at week 48 by ﬁ tting normal regression models 
with adjustment for randomised group and baseline 
values. Natural log transformations were applied as 
appropriate (for HIV-DNA, biomarkers and ratios of 
CD45RA [naive]:CD45RO [memory] cells and CD8RA 
[naive]:CD8RO [memory] cells). Change from baseline is 
presented as change from mean at baseline in all 
participants.
Categorical variables were compared with Fisher’s exact 
tests, or McNemar’s tests for paired data; rates used 
Poisson regression (including a random eﬀ ect for 
participant where appropriate). Generalised estimating 
equations (independent correlation structure) were used to 
compare self-reported adherence across randomised 
groups over time. Stata version 13.1 was used for all 
analyses (StataCorp 2013, College Station, TX, USA: 
StataCorp LP). To assess adherence to allocated strategy, 
the number of days that MEMS cap was opened at least 
once divided by number of days that MEMS cap was in use 
during the trial was calculated for each day of the week.
Pilot phase data were included in the analysis. The 
IDMC reviewed full interim data on three occasions, 
viral load and enrolment data at a fourth meeting, and 
analyses of viral load results alone on six further 
occasions during the trial.
The trial was registered with EudraCT, number 
2009-012947-40), ISRCTN, number 97755073, and CTA, 
number 27505/0005/001-0001.
Role of the funding source
The funders had no direct role in the study design, data 
collection, data analysis, data interpretation, report 
writing, or decision to submit the report for publication. 
The corresponding author had access to all data and 
responsibility for submission for publication.
Results
Between April 1, 2011, and June 28, 2013, 227 participants 
were screened (ﬁ gure 1), of whom 199 from 24 sites were 
randomly assigned (99 to short cycle therapy and 100 to 
continuous therapy). One participant in the continuous 
therapy group moved location and withdrew consent at 
week 24; the remaining 198 were followed up to at least 
week 48.
Of those patients randomly assigned, 70 (35%) were 
recruited from Uganda (35 in the short cycle therapy 
Figure 1: Trial proﬁ le
*One participant was unable to attend the randomisation visit due to a traﬃ  c accident and another participant was 
excluded because of unreliable attendance.
225 screened and consented
199 randomised
26 excluded
21 not meeting inclusion criteria
3 declined to participate
2 other reasons*
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99 allocated to short cycle therapy
99 received allocated intervention
100 allocated to continuous therapy
100 received allocated intervention
0 lost to follow-up
8 changed strategy to continuous therapy
6 due to reaching primary endpoint
1 poor adherence
1 adverse event
1 lost to follow-up
YP moved to a diﬀerent country
0 discontinued intervention
99 analysed
0 excluded from analysis
100 analysed
0 excluded from analysis
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group and 35 in the continuous therapy group), 
48 (24%) from western Europe, 36 (18%) from Thailand, 
20 (10%) from Ukraine, 14 (13%) from the USA, and 11 
(6%) from Argentina (appendix p 5). Baseline charac-
teristics were similar between the groups (table 1). 
Although CD4% and count were high and well matched 
between groups, fewer participants had CDC stage C 
disease in the short cycle therapy group than in the 
continuous therapy group. Pre-trial ART exposure was 
comparable between groups: median time on ART at 
randomisation was 6·1 years (IQR 3·8–8·4), 82 (41%) 
were on their initial ART regimen at baseline, 29 (15%) 
had previously substituted a protease inhibitor, but 
following the exclusion criteria, none had switched 
ART for failure.
13 participants had a conﬁ rmed viral load 50 of copies 
per mL or higher at any  time up to 48 weeks (table 2), an 
estimated probability of viral rebound of 6·1% in short 
cycle therapy versus 7·3% in continuous therapy 
(diﬀ erence –1·2%, 90% CI –7·3 to 4·9, test for diﬀ erence, 
bootstrap p=0·75; ﬁ gure 2A). Thus, the 4·9% upper band 
of the two-sided 90% conﬁ dence limit was well within 
the 12% non-inferiority margin. The per-protocol analysis 
gave a similar estimated diﬀ erence of –1·1% (90% CI 
–6·8 to 4·6), as did analysis without adjustment for 
stratiﬁ cation factors (ﬁ gure 2B).
After viral rebound, ﬁ ve (83%) of six participants in the 
short cycle therapy group resuppressed viral load (three 
on the same regimen but changed to continuous daily 
ART, two following regimen change) compared with only 
three (43%) of seven participants in the continuous 
therapy group (two resuppressed while continuing the 
same regimen and one after regimen change). The 
remaining ﬁ ve participants (one in the short cycle 
therapy group and four in the continuous therapy group) 
remained non-suppressed; three on ﬁ rst-line ART (one 
in the short cycle therapy group and two in the continuous 
therapy group) and two (in the continuous therapy 
group) after switching to second-line ART. Results 
repeating the primary analysis, adjusted for CDC stage at 
baseline were qualitatively unchanged: –1·3% diﬀ erence 
between groups, in favour of short cycle therapy (90% CI 
–7·4 to 4·7, test for diﬀ erence, bootstrap p=0·72).
To determine whether the risk of reaching the primary 
endpoint was related to type of NRTI (short-acting or 
long-acting), a Cox model adjusted for randomised group 
and NRTI received (zidovudine vs abacavir or tenofovir 
disoproxil fumarate) was ﬁ tted (exploratory analysis); 
results showed no signiﬁ cant diﬀ erences between 
continuous therapy and short cycle therapy (p=0·81; data 
not shown).
Six participants (two [2%] in the short cycle therapy 
group and four [4%] in the continuous therapy group) 
had conﬁ rmed viral load of 400 copies per mL or higher 
by week 48; estimated probability 2·1% in the short cycle 
therapy group versus 4·2% in the continuous therapy 
group (diﬀ erence –2·1%, 90% CI –6·2 to 1·9, p=0·38).
Short cycle therapy 
(n=99)
Continuous therapy 
(n=100)
Total (n=199)
Male 57 (58%) 48 (48%) 105 (53%)
Age (years) 13·7 (11·7–17·7) 14·4 (12·0–17·5) 14·1 (11·9–17·6)
8–12 38 (38%) 39 (39%) 77 (39%)
13–17 39 (39%) 41 (41%) 80 (40%)
18–24 22 (22%) 20 (20%) 42 (21%)
Ethnic origin
Black (African or other) 58 (59%) 54 (54%) 112 (56%)
White 24 (24%) 17 (17%) 41 (21%)
Asian 15 (15%) 22 (22%) 37 (19%)
Other 2 (2%) 7 (7%) 9 (5%)
Route of infection
Vertical 90 (91%) 90 (90%) 180 (90%)
Sexual contact 7 (7%) 7 (7%) 14 (7%)
Unknown/other* 2 (2%) 3 (3%) 5 (3%)
CDC stage†
N 16 (16%) 10 (10%) 26 (13%)
A 25 (25%) 25 (25%) 50 (25%)
B 45 (45%) 43 (43%) 88 (44%)
C 13 (13%) 21 (21%) 34 (17%)
Cumulative ART exposure before 
baseline (years)
6·2 (3·8–7·9) 5·9 (4·0–8·4) 6·1 (3·8–8·4)
Baseline regimen is the initial 
ART regimen
40 (40%) 42 (42%) 82 (41%)
Efavirenz plus
Zidovudine plus lamivudine 52 (53%) 53 (53%) 105 (53%)
Tenofovir plus lamivudine or 
emtricitabine
25 (25%) 27 (27%) 52 (26%)
Abacavir plus lamivudine or 
emticitabine
22 (22%) 18 (18%) 40 (20%)
Other‡ 0 (0%) 2 (2%) 2 (1%)
CD4 percentage 34·5 (29·3–39·0) 34·0 (29·5–38·1) 34·0 (29·5–38·5)
<25% 5 (5%) 6 (6%) 11 (6%)
≥25% to <40% 73 (74%) 76 (76%) 149 (75%)
≥40% 21 (21%) 18 (18%) 39 (20%)
CD4 cell count (cells per μL) 722·5 (581·0–965·0) 747·3 (575·3–972·8) 735·0 (575·5–967·5)
≥350–500 16 (16%) 12 (12%) 28 (14%)
>500 83 (84%) 88 (88%) 171 (86%)
Viral load (copies per mL)
<20§ 91 (93%) 86 (91%) 177 (92%)
≥20 7 (7%) 8 (9%) 15 (8%)
Total HIV-1 DNA (copies per 
million cells)
420 (159–871) 309 (136–926) 347 (145–894)
Interleukin 6 (pg/mL) 0·6 (0·4–0·9) 0·6 (0·4–0·9) 0·6 (0·4–0·9)
D-dimers (ng/mL) 69·1 (3·13–135·4) 65·7 (4·8–80·3) 67·5 (3·1–152·2)
CRP (pg/mL) 631·2 (303·8–2676·1) 621·6 (260·8–2164·1) 626·8 (288·8–2311·0)
Data are median (IQR) or n (%). CDC=US Centers for Disease Control and Prevention. ART=antiretroviral therapy. 
CRP=C-reactive protein. *Three young people acquired HIV through blood products (one in the short cycle therapy 
group and two in the continuous therapy group), two had uncertain methods of transmission (one in the continuous 
therapy group and one in the short cycle therapy group).†One young person in the continuous therapy group with 
unknown US CDC stage at randomisation. ‡The remaining nucleotide reverse transcriptase inhibitor backbones in 
two patients were (1) zidovudine plus lamivudine plus tenofovir and (2) didanosine plus abacavir. §Seven samples 
(one in the short cycle therapy group and six in the continuous therapy group) were not available for testing with an 
ultra-sensitive assay.
Table 1: Baseline characteristics 
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12 participants changed ART regimen during the ﬁ rst 
48 weeks (three in the short cycle therapy group and 
nine in the continuous therapy group, Fisher’s exact 
p=0·13), ﬁ ve because of toxic eﬀ ects (one in the short 
cycle therapy group and four in the continuous therapy 
group; tables 2, 3).
Of 13 participants reaching the primary endpoint, 
resistance results were available for nine (three in the 
short cycle therapy group and six in the continuous 
therapy group); the remaining four patients had samples 
with low viral load, insuﬃ  cient to obtain a result (three in 
the short cycle therapy group: 56 copies per mL, 
62 copies per mL, and 126 copies per mL; one in the 
continuous therapy group: 231 copies per mL). All four 
participants suppressed again after these blips, 
suggesting drug resistance was unlikely. Seven of nine 
participants with available results had resistance 
mutations: all seven had NNRTI mutations and two had 
Met184Val (table 2).
No new CDC stage C and two CDC stage B events were 
recorded (bronchopneumonia in the short cycle therapy 
group and bronchitis in the continuous therapy group) 
and no signiﬁ cant diﬀ erences were noted between 
groups in CD4% or CD4 cell count (table 2). With the 
exception of lower mean corpuscular volume in those on 
zidovudine and lower platelet levels in the short cycle 
therapy group compared with the continuous therapy 
group; haematological variables did not diﬀ er (appendix 
p 6). Concentration of low density lipoproteins was 
higher at week 24 in the short cycle therapy group than in 
the continuous therapy group, but we observed no 
diﬀ erence at week 48 (appendix p 6).
By week 48, eight participants in the short cycle therapy 
group had reverted to continuous therapy: six participants 
reached the primary endpoint, one developed gynaeco-
mastia leading to efavirenz discontinuation and 
Short cycle 
therapy (n=99)
Continuous 
therapy (n=100)
p value
Primary endpoint
Participants with conﬁ rmed viral load 
≥50 copies/mL
6 (6%) 7 (7%) 0·75
Secondary endpoints
Participants with conﬁ rmed viral load 
≥400 copies/mL
2 (2%) 4 (4%) 0·38
Participants with change in ART regimen 3 (3%) 9 (9%) 0·13
Viral rebound 0 1 ..
Toxicity* 1 4 ..
Adherence problems 1 1 ..
Simpliﬁ cation 1 3 ..
Participants with mutations present at viral 
rebound† (participants with resistance test 
result available)
2 (3) 5 (6) 1·00
Number of NNRTI mutations
None 1 1 ..
1–2 1 5 ..
3 or more 1 0 ..
Number of NRTI mutations
None 2 5 ..
1 1 1 ..
Mean change in CD4 percentage (%) 0·2% (0·4) 0·1% (0·4) 0·76
Mean change in absolute CD4 count 
(cells per μL)
–34·2 (20·9) –21·6 (21·1) 0·67
Substudy results n=98 n=94
Viral load
≥20 copies/mL at week 48 13 (13%) 14 (15%) 0·84
<20 copies/mL at week 48 85 (87%) 80 (85%)
Mean change in total HIV-1 DNA (Ln copies 
per million cells)
0·1 (0·1) –0·2 (0·1) 0·13
Mean change in interleukin 6 (Ln pg/mL) 0·0 (0·1) 0·1 (0·1) 0·64
Mean change in D-dimers (Ln ng/mL) –0·5 (0·2) –0·0 (0·2) 0·05
Data are n (%) or mean change from randomisation (SE), unless otherwise stated. ART=antiretroviral therapy. 
NRTI=nucleoside/nucleotide reverse transcriptase inhibitors. NNRTI=non-nucleoside reverse transcriptase inhibitor. 
Ln=natural logarithm. *One gynaecomastia in the short cycle therapy group, three lipodystrophy events with onset 
before baseline in the continuous therapy group, and one raised transaminases in the continuous therapy group. 
†Two participants on short cycle therapy: (1) Leu100Ile, Lys103Asn, Tyr188Cys and (2) Lys103Asn, Met184Val; 
ﬁ ve  participants on continuous therapy: (1) Val106, Glu138Ala, (2) Lys103Asn, Val106Met, (3) Met230Leu, 
(4) Lys103Asn, Val106Met, and (5) Met184Val, Glys190Ser; samples from four additional patients (three in the 
short cycle therapy group and one in the continuous therapy group) with low level viraemia failed to amplify.
Table 2: Trial eﬃ  cacy from randomisation to week 48 assessment 
Figure 2: Time to viral rebound
(A) Kaplan-Meier graph adjusted for stratiﬁ cation factors—time from 
randomisation to viral rebound (conﬁ rmed viral load ≥50 copies per mL). 
(B) Estimated diﬀ erence in proportion of participants with viral rebound 
(two-sided 90% CI) between short cycle therapy and continuous therapy at 
week 48 for diﬀ erent analyses. *Diﬀ erence in estimated probability of viral 
rebound, Kaplan-Meier methods, with adjustment for study stratiﬁ cation 
factors. †Diﬀ erence in estimated probability of viral rebound, Kaplan-Meier 
methods. ‡With exact conﬁ dence intervals. §Kaplan-Meier methods, censoring 
individuals who violated the proﬁ le at that time, with adjustment for study 
stratiﬁ cation factors.
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resumption of daily ART, and one had ART changed for 
poor adherence (without reaching the primary endpoint).
By 48 weeks, 20 participants had 27 grade 3 or 4 adverse 
events, with decreased neutrophil count being the most 
common (two participants in the short cycle therapy 
group vs six participants in the continuous therapy group; 
Fisher’s exact p=0·28; table 3). Two ART-related adverse 
events were reported in two participants in the short cycle 
therapy group compared with 14 events in ten participants 
in the continuous therapy group (Poisson p=0·02 for 
number of events; Fisher’s exact p=0·03 for number of 
participants); this was the only signiﬁ cant diﬀ erence in 
adverse events between groups). Lipodystrophy and 
gynaecomastia were the most common ART-related 
events. 13 serious adverse events were reported in nine 
participants (six in the short cycle therapy group and 
three in the continuous therapy group; table 3). There 
were ﬁ ve pregnancies (one in the short cycle therapy 
group and four in the continuous therapy group).
Among 192 children (98 in the short cycle therapy 
group and 94 in the continuous therapy group) in the 
immunology and virology substudy, values for viral load 
less than 20 copies per mL, total HIV-1 DNA, and 
inﬂ ammatory markers, including interleukin 6 and 
D-dimer, were similar between randomised groups at 
baseline (table 1; appendix p 7). At week 48, 13 (13%) 
children in the short cycle therapy group and 14 (15%) in 
the continuous therapy group had viral load 20 copies 
per mL or higher (Fisher’s exact p=0·84) and there were 
no signiﬁ cant diﬀ erences between groups in total HIV-1 
DNA (table 2; p=0·13), including after adjustment for 
diﬀ erences at baseline or after exclusion of participants 
with evidence of viral rebound (data not shown). No 
diﬀ erences between groups were noted at week 48 in the 
19 biomarkers of inﬂ ammation, vascular injury, and 
disordered thrombogenesis, with the exception of 
D-dimer, which was lower in the short cycle therapy 
group than in the continuous therapy group by log 0·5 
(p=0·05; table 2; appendix p 7). No diﬀ erences were 
identiﬁ ed in CD8 cells, ratios of CD45RA (naive):CD45RO 
(memory) cells, and CD8RA (naive):CD8RO (memory) 
cells between groups at week 48 (data not shown).
In the short cycle therapy group, 95% of weekend 
breaks were reported as taken (99% excluding time 
after return to continuous therapy). The MEMS cap 
substudy data supported these results. Among 
61 participants enrolled in the substudy (31 in the short 
cycle therapy group and 30 in the continuous therapy 
group), 56 (28 in each group) continued to use MEMS 
caps until 36 weeks and 46 (23 in each group) were still 
using MEMS caps at week 48. The median number of 
cap openings per week was ﬁ ve (IQR 4–5) in the short 
cycle therapy group and seven (6–7) in the continuous 
therapy group. MEMS caps were opened at least once 
daily from Monday to Friday more than 80% of the time 
in both groups, with the percentage of bottle openings 
remaining high in the continuous therapy group at 
weekends, but dropping to less than 20% for those on 
short cycle therapy (ﬁ gure 3).
Based on ART logs, updated at each visit, one 
participant in the short cycle therapy group and seven 
Short cycle 
therapy 
(n=99)
Continuous 
therapy 
(n=100)
Total 
(n=199)
Grade 3 and 4 adverse events 13 (8) 14 (12) 27 (20)
Clinical
Infections and infestations 3 1 4
Nervous system disorders* 2 1 3
Skin and subcutaneous tissue 
disorders
0 1 1
Surgical and medical procedures 0 2 2
Kaposi’s sarcoma (AIDS related) 1 0 1
Suicidal ideation 0 1 1
Gynaecomastia 1 0 1
Laboratory
Neutropenia 2 6 8
Low density lipoprotein 
cholesterol increased
1 1 2
Bilirubin increased 1 0 1
Calcium decreased 1 0 1
Glucose decreased 1 0 1
Alkaline phosphatase increased 0 1 1
ART-related adverse events (all 
grades)
2 (2) 14 (10) 16 (12)
Lipodystrophy† 0 5 5
Gynaecomastia 1 2 3
Suicidal ideation 0 1 1
Dizziness 0 1 1
Headache and syncope 0 1 1
Spontaneous abortion 1 1 2
Neutropenia 0 1 1
Raised transaminases 0 2 2
Treatment-modifying adverse 
events (all grades)‡
1 (1) 4 (4) 5 (5)
Serious adverse events§ 7 (6) 6 (3) 13 (9)
Serious adverse event rate per 
100 person-years (95% CI)
6·9 
(3·3–14·4)
5·9 
(2·6–13·1)
6·4 
(3·7–10·9)
Data are number of episodes (number of participants), unless otherwise stated. 
ART=antiretroviral therapy. The only signiﬁ cant diﬀ erence in numbers of adverse 
events or number of patients with adverse events were in ART-related adverse 
events (Poisson p=0·02, Fisher’s exact p=0·03, respectively). *One headache 
(short cycle therapy group), one hemiparesis (short cycle therapy group), and one 
collapse or suspected seizure (continuous therapy group). †Lipodystrophy events 
(continuous therapy group): two new and three worsening events with onset 
before baseline. ‡One gynaecomastia (short cycle therapy group), three 
worsening lipodystrophy events with onset before baseline (continuous therapy 
group), and one raised concentration of transaminases (continuous therapy 
group). §Serious adverse events in the short cycle therapy group: ﬁ ve admissions 
to hospital (one headache, one exacerbation of bronchiectasis, one Kaposi’s 
sarcoma, one measles, and one epistaxis) and two other important medical 
conditions (one spontaneous abortion and one transient hemiparesis); in the 
continuous therapy group:  one life threatening (suicidal ideation), four 
admissions to hospital (one contusion of chest, one collapse or suspected seizure, 
one spontaneous abortion, and one appendicitis) and one other important 
medical condition (neurosyphilis).
Table 3: Adverse events from randomisation to week 48 assessment 
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participants in the continuous therapy group had a 
treatment interruption of 3 days or more (excluding 
weekend breaks in the short cycle therapy group; Fisher’s 
exact test p=0·07). Adherence questionnaires were 
completed by 91 participants in the short cycle therapy 
group and 93 participants in the continuous therapy 
group at one or more visit (80 in both groups at four or 
more visits) to 48 weeks. Adherence was similar in both 
groups with 7% (29 of 414) of reports in the short cycle 
therapy group versus 10% of (40 of 409) reports in the 
continuous therapy group of missing ART in the week 
prior to the assessment visit (excluding weekend breaks 
in the short cycle therapy group; p=0·42). Adherence 
based on carers’ questionnaires was also similar between 
the two groups (data not shown).
In acceptability questionnaires completed at baseline, 
70 (88%) of 80 participants in the short cycle therapy 
group thought the approach would be easier than staying 
on continuous therapy. At end of follow-up 81 (90%) of 
90 participants in the short cycle therapy group reported 
that weekend breaks made life easier than daily ART, 
mainly because going out with friends was easier: 
15 (20%) of 76 participants who completed both question-
naires reported this was diﬃ  cult pre-trial compared with 
only two of 76 during the trial (McNemar p=0·001; 
appendix p 8). The acceptability of short cycle therapy as 
further explored in the qualitative substudy will be 
reported elsewhere.17
Discussion
We found no evidence that short cycle therapy was 
inferior to continuous therapy in maintaining viral load 
suppression with a very small non-signiﬁ cant diﬀ erence 
between the groups favouring short cycle therapy. 
Further, ﬁ ve of six participants on short cycle therapy 
who had low level viraemia resuppressed on returning to 
daily ART. Results were essentially unchanged in further 
analyses that adjusted for small diﬀ erences in CDC stage 
at baseline, and were done per protocol. Our results have 
broad generalisability because we recruited participants 
from diverse geographical, ethnic, and sociocultural 
backgrounds in 11 countries, including 21% who were 
young adults in their early twenties.
There were fewer major resistance mutations among 
children failing on short cycle therapy than in those on 
continuous therapy, although this was not statistically 
signiﬁ cant. In both groups and similarly to the 
PENPACT-1 trial, which assessed timing of switch to 
second-line ART, NNRTI and Met184Val mutations 
emerged rapidly even at low level viraemia.20
Although virological suppression to less than 
50 copies per mL was the primary endpoint, we further 
investigated the safety of short cycle therapy by assessing 
its eﬀ ect on very low level viraemia and HIV reservoir 
and showed no diﬀ erences between the short cycle 
therapy and continuous therapy groups. Methods of 
varying technical diﬃ  culty and biological meaning have 
been suggested to quantify the HIV reservoir, which is 
responsible for viral rebound following treatment 
interruption.21 We measured HIV-1 DNA because it is a 
surrogate for reservoir size in acute and chronic HIV 
infection.22,23
Increases in chronic immune activation and inﬂ am-
mation have been reported in adult interruption trials 
designed to allow rebounds in viral load, and have been 
associated with adverse HIV-related outcomes.24 Immune 
activation with raised concentrations of biomarkers of 
inﬂ ammation and coagulation has also been reported in 
patients with virological suppression,25 both among elite 
controllers not on ART and ART recipients with 
supressed viral load, albeit at low levels.26 Therefore, we 
also measured the eﬀ ect of the short cycle therapy 
strategy on 19 potentially important biomarkers and 
found no evidence of any diﬀ erences between groups, 
with the exception of D-dimer which, by contrast with 
expectation, was lower in short cycle therapy than in 
continuous therapy, which could be a chance ﬁ nding. 
The absence of a signal suggestive of any increased 
immune activation and inﬂ ammation adds further 
conﬁ dence that the short cycle therapy strategy was not 
causing subclinical injury. Furthermore, we recorded no 
diﬀ erences in cellular markers previously shown to be 
rapidly deranged during treatment interruption.27
Most safety proﬁ les were similar between randomised 
groups, and there were more ART-related adverse events 
reported in the continuous therapy group. However, in 
an open-label trial, potential for reporting bias exists.
Assuring adherence to the randomised strategy is 
crucial to the integrity of trial results. If participants 
randomly assigned to the continuous therapy group 
elected, of their own accord, to take breaks in therapy, 
non-inferiority of short cycle therapy and continuous 
therapy might be shown, because both groups could be 
taking similar breaks oﬀ -ART. Three independent 
Figure 3: Proportion of days MEMS caps were opened
Data for 31 participants in the short cycle therapy group and 30 participants in the continuous treatment group 
(including 23 in each group with data to 48 weeks). MEMS=Medication Event Monitoring System. 
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indicators of adherence to assigned strategy (self-reported 
adherence, MEMS caps substudy, and diﬀ erences 
between groups in mean corpuscular volume  among 
zidovudine recipients) all showed that participants on 
short cycle therapy had appropriately less ART exposure 
than those on continuous therapy.
As well as being the ﬁ rst randomised trial in children, 
our results build on those from two adult trials with 
similar design, showing non-inferiority of short cycle 
therapy versus continuous therapy on efavirenz-based 
ART.10,15 Only one non-randomised study of short cycle 
therapy in US adolescents and young adults has been 
reported in heavily ART-experienced participants taking 
a 3 day weekend break from protease inhibitor-based 
ART regimens.12 This study diﬀ ered substantially from 
our study and the adult short cycle therapy trials in both 
design and ART used. More than a third of participants 
had viral rebound and more than half changed to 
continuous treatment for other reasons; with no control 
group and multiple previous ART regimens, viral load, 
and resistance test results are hard to interpret or 
compare with our trial. Protease inhibitor ART might not 
be ideal for short cycle therapy because half-lives are 
shorter than NNRTIs and might not protect against viral 
replication during days oﬀ . Furthermore, participants in 
the US study had breaks of 3 days, whereas those in our 
trial had breaks of only 2 days.
Acceptability of the short cycle therapy strategy was 
shown among participants from all backgrounds; in 
particular, it was valued because it allowed for more 
socialising with friends at weekends. Similar results 
were reported in the associated qualitative substudy, 
during which participants also discussed liking short 
cycle therapy because of perceived reduction of previously 
unreported and unrecognised ART side-eﬀ ects, such as 
dizziness and reduced energy. The qualitative substudy17 
provided insights into the complexities of physician–
patient interactions, particularly relating to non-
adherence. In particular, participants who are virologically 
suppressed might elect not to disclose adherence lapses 
because of a desire not to fail or disappoint their 
physician. Overall, the qualitative ﬁ ndings endorsed 
participants’ enthusiasm for short cycle therapy, but also 
highlighted the need for support with early adaptation to 
weekend breaks oﬀ -ART.17
The overall reduction in drug exposure could reduce 
long-term toxicity for individuals and, at a population 
level, result in cost savings, enabling more participants 
to receive treatment. The ENCORE1 trial28 showed that 
daily 400 mg efavirenz was non-inferior to 600 mg, with 
less toxicity; in both groups, efavirenz was given with 
daily tenofovir and emtricitabine. Efavirenz 400 mg 
daily is included as an alternative option to 600 mg 
efavirenz-based ART in revised WHO 2016 adult 
guidelines.29 Of note, the weekly cumulative dose of 
daily 400 mg efavirenz is almost the same as in our trial. 
Both strategies seem to be more acceptable to patients 
than 600 mg daily efavirenz and provide the possibility 
of individualisation of ART regimens to suit life 
situations.
The results from this study show that short cycle 
therapy might be a promising strategy for adherent 
children and adolescents well established on ART. 
However, follow-up is relatively short. A 2-year trial 
extension is ongoing, which will provide further data on 
longer-term sustainability. More than 90% of participants 
have reconsented to stay on their randomised strategy 
and we expect results in 2017. Of note, this short cycle 
therapy strategy can be generalised only to children and 
young people taking efavirenz-based ART who have not 
had treatment failure, and where there is availability of 
viral load monitoring. Appropriate counselling and 
support is needed to explain that there should be a 
maximum of 2 days per week breaks in therapy. 
Furthermore, results presented here cannot necessarily 
be extrapolated to ART containing the reduced dose of 
efavirenz (equivalent to 400 mg for adults) or other ART 
regimens, or to settings where viral load monitoring is 
unavailable or infrequent. Further research is needed to 
address this, and could also assess short cycle therapy 
with other suitable long-acting drugs or drugs with a 
higher barrier to resistance such as tenofovir alafenamide 
and dolutegravir .30
In conclusion, in an adherent and geographically 
diverse population of HIV-infected 8–24 year-olds on 
600 mg efavirenz-based ART, a short cycle therapy 
strategy with 2-day weekend breaks was non-inferior to 
continuous therapy in terms of virological, immuno-
logical, inﬂ ammatory eﬀ ects, and resulted in fewer 
adverse events. Treatment with ART 5 days per week 
instead of 7 provides potential for cost savings. Short 
cycle therapy was liked by participants; in particular, it 
improved their social lives. This short cycle therapy 
strategy is a viable option for adherent HIV-infected 
young people who are stable on efavirenz-based ART. 
Ongoing longer-term follow-up will further inform 
sustainability and further research is required for settings 
where viral load monitoring is less accessible.
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